

KERYX BIOPHARMACEUTICALS INC  
Form 8-K  
February 25, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): February 25, 2016**

**Keryx Biopharmaceuticals, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**000-30929**  
**(Commission**  
  
**File Number)**  
**One Marina Park Drive, 12<sup>th</sup> Floor**  
  
**Boston, Massachusetts 02210**

**13-4087132**  
**(IRS Employer**  
  
**Identification No.)**

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

**(Address of Principal Executive Offices)**

**(617) 466-3500**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act.
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

**Item 2.02. Results of Operations and Financial Condition.**

On February 25, 2016, Keryx Biopharmaceuticals, Inc. ( Keryx ) issued a press release announcing its results of operations for the fourth quarter and year ended December 31, 2015. Keryx also announced that on February 25, 2016 at 8:00 a.m. ET, it will host an investor conference call to discuss the Company's fourth quarter and year-end 2015 financial results and provide a business outlook for 2016. A copy of such press release is being furnished as Exhibit 99.1 to this report and is incorporated herein by reference. A copy of the PowerPoint presentation to be used on the investor conference call is being furnished as Exhibit 99.2 to this report and is incorporated herein by reference.

The information set forth in Exhibits 99.1 and 99.2 shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements And Exhibits.**

(d) Exhibits.

The following exhibits are furnished herewith:

- 99.1 Press release issued by Keryx Biopharmaceuticals, Inc., dated February 25, 2016.
- 99.2 PowerPoint presentation to be presented by Keryx Biopharmaceuticals, Inc. on February 25, 2016.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Keryx Biopharmaceuticals, Inc.**  
(Registrant)

Date: February 25, 2016

By: /s/ Brian Adams  
Brian Adams  
General Counsel and Corporate Secretary

**INDEX TO EXHIBITS**

**Exhibit**

<b>Number</b>	<b>Description</b>
99.1	Press release issued by Keryx Biopharmaceuticals, Inc., dated February 25, 2016.
99.2	PowerPoint presentation to be presented by Keryx Biopharmaceuticals, Inc. on February 25, 2016.